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Abstract. COM1 (candidate of metastasis 1) has been recently 
shown to influence the metastatic ability of cancer cells and 
disease progression of certain solid tumours. The role of COM1 
in bladder cancer remains unknown. In the present study, we 
examined the expression of the COM1 protein in human bladder 
tissues, and also its effect on growth, adhesion, migration and 
invasion of human bladder cancer cells, in vitro. The expression 
of COM1 in human bladder tissues and bladder cancer cell lines 
was assessed at both the mRNA and protein levels using RT-PCR 
and immunohistochemistry, respectively. COM1 staining was 
compared with tumour staging. Mammalian COM1 expression 
construct and anti-COM1 ribozyme transgenes were used to 
generate sublines of human bladder cancer cells with differ-
ential expression of COM1. The effect of COM1 on cellular 
functions was examined in bladder cancer cells with which 
COM1 was overexpressed or knocked down using a variety of 
in vitro assays. In normal bladder tissues, stronger staining of 
COM1 was seen in the cytoplasm of normal urothelial cells. 
In contrast, the staining was notably weak or absent in cancer 
cells of tumour tissues and invasive tumours had significantly 
low levels of staining compared with non-invasive tumours 
(p=0.012). Knockdown of COM1 in bladder cancer cell lines 
resulted in an increase in cellular growth and invasion, while 
overexpression of COM1 suppressed invasiveness and growth 
of these cells. Further investigation revealed an increased apop-
tosis and upregulated p21 in bladder cancer cells when COM1 
was overexpressed. COM1 is expressed at low levels in human 
bladder cancer and in particular in invasive bladder tumours. 
COM1 levels are inversely correlated with the invasiveness and 
growth of bladder cancer cells in vitro. Induced apoptosis and 
upregulation of p21 are indicated in the mechanism of COM1 
inhibiting bladder cancer cell growth. It suggests that COM1 is 
a potential tumour suppressor in human bladder cancer.
Introduction
COM1 (candidate of metastasis 1) was initially found to be 
upregulated in the metastatic lesions of the central nervous 
system upon injection of cancer cells originally isolated from 
micrometastases in the bone marrow of a breast cancer patient (1). 
Subsequently COM1 was found to be the human counterpart of 
the rat p8, which was first reported as a new gene and strongly 
activated in pancreatic acinar cells during the acute phase of 
pancreatitis in rat described by Mallo et al (2). COM1/P8 also 
known as nuclear protein transcriptional regulator 1 (NUPR1), 
is located on chromosome 16 at position p11.2. The COM1 gene 
encodes two isoforms in protein products, one with 100 amino 
acids, the other with 82 amino acids. The role of the 18 amino 
acids region absent in the latter is presently unclear.
Overexpression of COM1 has been indicated in the 
pancreatic cancer and thyroid cancer (3,4). Su et al reported 
that COM1 was overexpressed in 59% of the 44 pancreatic 
cancer cohort. In addition, its expression was inversely corre-
lated to apoptosis in pancreatic cancer. However, COM1 did 
not have any significant correlation with the overall survival 
of the patients with pancreatic cancer. Moreover, COM1 was 
more prominent in lower age group patients, moderately or 
poorly differentiated cancers and lymph node positive cases. 
Overexpression of COM1 and loss of apoptosis were signifi-
cantly correlated with poor differentiation and lymph node 
metastasis. This interesting expression pattern might reflect not 
only the growth activity and differentiation of cancer cells but 
also invasion and metastasis of human pancreatic cancer (3). 
Ito et al reported that COM1 was significantly overexpressed 
in thyroid papillary carcinomas and that COM1 overexpression 
was more frequently observed in larger papillary carcinoma 
with lymph node metastasis (4).
On the other hand, reduced expression of COM1 was 
revealed in other cancer types including breast and prostate 
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cancer. Breast cancer cells have markedly reduced nuclear 
distribution of the COM1 protein compared with normal 
mammary epithelial cells. Low levels of COM1 were associated 
with nodal status and poor clinical outcome (5). A follow-up 
study showed that the nuclear presence of the COM1 protein 
was crucial to its inhibitory role in cancer cells, and that loss of 
its nuclear presence of this molecule had a detrimental effect on 
its overall negative control of cancer growth (6). Compared with 
normal prostate tissues, the expression of COM1 in prostate 
cancer cells was substantially reduced. Knockdown of COM1 
in prostate cancer cells resulted in increased cellular motility 
and growth. In contrast, overexpression of COM1 suppressed 
invasiveness and growth of prostate cancer cells and tumour 
growth in vivo. COM1 was proposed to act as a potential 
tumour suppressor in prostate cancer (7). Collectively these 
studies suggest that COM1 plays contrasting roles in different 
malignancies. Although the mode of action of COM1 in cancer 
cells remains unclear, it has been recently indicated that Com1 
may be connected to doxobubicin-indued chemoresistence in 
cancer cells and that this may be linked to the regulation of p53 
and p21 (8).
Although COM1 has been implicated in the disease 
progression of certain solid tumours including prostate cancer, 
its role in bladder cancer remains unknown. In the present study 
we first examined the expression of COM1 in normal bladder 
tissues and bladder tissues with different invasion status and 
the effect of COM1 on growth, adhesion, migration and inva-
sion of bladder cancer cells.
Materials and methods
Materials, cell lines and tissue samples. Human bladder cancer 
cell lines RT112, EJ138 and T24 (ECACC, European Collection 
of Animal Cell Culture, Salisbury, UK) were routinely main-
tained in DMEM-F12 medium supplemented with 10% fetal 
bovine serum and antibiotics. Polyclonal goat anti-COM1 
(SC-23283) and monoclonal mouse anti-GAPDH (SC-32233) 
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). Other reagents or kits were obtained from Sigma-Aldrich, 
Poole, UK.
Bladder tissues samples (n=37, including 14 non-invasive, 
18 invasive and 5 normal bladder tissues) were obtained from the 
Department of Urology, Chaoyang Hospital, Beijing, China. All 
protocols were reviewed and approved by the Ethics Committee 
and all patients gave written informed consent.
Immunohistochemical staining procedure for bladder 
tissues. Thin paraffin tissues sections were first dewaxed 
using the gradient xylene/ethanol solutions. Antigen retrieval 
was carried out using an EDTA antigen retrieving buffer in 
microwave (25 min). After blocking the endogenous peroxi-
dase, the sections were incubated for 20 min in a horse serum 
blocking solution and probed with the primary antibody 
(1 h). Following extensive washing, sections were incubated 
for 30 min with a biotinylated secondary antibody (multilink 
swine anti-goat/mouse/rabbit immunoglobulin, Dako Inc. 
Carpinteria, CA, USA). Following washing, an avidin-biotin 
complex (Vector Laboratories) was applied to the sections 
followed by extensive washing. Diamino benzidine chro-
mogen (Vector Laboratories) was then added to the sections, 
which were incubated in the dark for 5 min. Sections were 
then counterstained in Gill's haematoxylin and dehydrated in 
ascending grades of methanol before clearing in xylene and 
mounting under a cover slip. Staining of COM1 was assessed 
using a method modified from Allred IHC scoring system (9). 
Score 0, 1, 2 and 3 was given to the staining being negative, 
faint, moderate and strong, respectively.
Construction of COM1 expression vectors and transfection. 
The first strand cDNA was synthesized from RNA isolated 
from normal human mammary tissues using a DuraScript™ 
RT-PCR kit. PCR was then used to amplify the coding 
sequence of human COM1 using the Extensor Hi-Fidelity 
PCR Master mix (ABgene Ltd., Epsom, UK). The sequences 
of primers are shown in Table I. The verified COM1 insert was 
cloned into a mammalian expression plasmid vector (pEF/His 
TOPO TA plasmid vector, Invitrogen Inc., Paisley, UK). The 
recombinant plasmid vectors were transformed into chemically 
competent TOP10 E. coli (Invitrogen), and the colonies were 
then analyzed. Colonies carrying correct recombinant plas-
mids were amplified and plasmids extracted. Purified COM1 
transgenes and control plasmid vectors were then transfected 
into RT112 and EJ138 cells individually using an Easjet Plus 
electroporator (EquiBio Ltd, Kent, UK). After up to 3 weeks 
of selection with blasticidin the transfectants were verified for 
their expression of COM1 and successful clones were used in 
subsequent studies.
Generation of COM1 ribozyme transgenes. Anti-COM1 
hammerhead ribozyme transgenes were synthesised and 
cloned into pEF6/V5-His-TOPO plasmid vector as described in 
Table I. Primer sequences for PCR.
Primer Forward Reverse
COM1 CCTGGATGAATCTGACCTC AGCAGCTTCTCTCTTGGTG
COM1 expression ATGGCCACCTTCCCAC ACTGCGCCGTGCCCCTCG
COM1 ribozyme CTGCAGCTTCTCTCTTGGTGCCTGATGAGTCC ACTAGTGGAGGCCGGAAAGGTTTCGTCC
 GTGAGGA TCACGGACT
uPA GGTTGTGTGTGGGTTAGACT GTGGCTACCAGACATTGATT
p21 CGGGATGAGTTGGGAGGAG ACAGGTCCACATGGTCTTCC
C-myc TGCTCCATGAGGAGACAC TTTCATTGTTTTCCAACTCC
GAPDH GGCTGCTTTTAACTCTGGTA GACTGCGGTCATGAGGCCGT
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previous studies (5-7). Empty plasmid vectors and the ribozyme 
transgenes were then transfected into RT112 and EJ138 cells 
and the cells underwent selection with 5 µg/ml blasticidin for 
approximately 2 weeks before verification.
RNA isolation and reverse transcription PCR. RNA was 
isolated using total-RNA Isolation Reagent (ABgene Ltd). 
Reverse transcription was performed using the DuraScript™ 
RT-PCR kit, followed by PCR using a REDTaq™ ReadyMix 
PCR reaction mix (primer sequences shown in Table I). 
Cycling conditions were 94˚C for 5 min, followed by 30 cycles 
of 94˚C for 30 sec, 55˚C for 30 sec and 72˚C for 40 sec. This 
was followed by a final 10-min extension period at 72˚C. The 
products were visualized on 2% agarose gel stained with 
ethidium bromide.
Immunoprecipitation and western blot analysis. The protein 
concentration in cell lysates were determined using the DC 
Protein Assay kit (Bio-Rad) and an ELx800 spectrophotom-
eter (Bio-Tek™). Equal amount of proteins were separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and blotted onto nitrocellulose sheets. Proteins 
were then respectively probed with anti-COM1 antibody 
and peroxidase-conjugated secondary antibody, with 
stringent washings between each step. Protein bands were 
visualized using the Supersignal™ West Dura system (Pierce 
Biotechnology, Inc., Rockford, IL, USA), and photographed 
using a UVITech imager (UVITech Inc., Cambridge, UK).
In vitro cell growth assay. Cells were plated into a 96-well 
plate (3,000 cells/well). Cell growth was assessed after a 
period of incubation (up to 5 days). Crystal violet was used to 
stain cells. Following washing, stained crystal was extracted 
with 10% acetic acid and absorbance was determined at a 
wavelength of 540 nm using a spectrophotometer (Elx800, 
Bio-Tek, Potton, UK).
In vitro invasion assay. Transwell inserts with 8 µm pore size 
were coated with 50 µg Matrigel (BD Matrigel™ Basement 
Membrane Matrix) and air dried. The Matrigel was rehydrated 
before use. Cells (30,000) were added to each insert, same 
number cells were loaded into another well as control. After 
96 h cells that had migrated through the matrix to the other 
side of the insert were fixed in 4% formalin, stained with 0.5% 
(w/v) crystal violet. The stained crystal was extracted with 10% 
acetic acid and absorbance was determined at a wavelength 
of 540 nm using a spectrophotometer (Bio-Tek, Elx800). 
Percentage of invaded cells was calculated as absorbance of 
invaded cells divided by absorbance of control cells.
Flow cytometric analysis of apoptosis. All cells including those 
floating in the culture medium were harvested after a period of 
incubation. Cells were washed in ice cold PBS and resuspended 
in 1X Annexin-binding buffer at a density of 1x106 cells/ml after 
centrifugation. FITC Annexin V (5 µl) and PI working solution 
(1 µl) (100 µg/ml) (Molecular Probes, Eugene, OR, USA) were 
added to 100 µl of the cell suspension. After a 30-min incuba-
tion at room temperature, 400 µl of 1X Annexin-binding buffer 
was added, mixed gently and the samples were kept on ice. 
The stained cells were immediately analyzed using the flow 
cytometer and FlowMax software package.
Statistical analysis. Statistical analysis was performed using the 
Minitab statistical software package (version 14). Non-normally 
distributed data were assessed using the Mann-Whitney test, 
while the two sample t-test was used for normally distributed 
data. χ2 test was used to analyse the IHC staining of COM1 in 
bladder specimens. Differences were considered to be statisti-
cally significant at p<0.05.
Results
Expression of COM1 in human bladder tissues. We first exam-
ined the protein expression of COM1 in human bladder tissues 
using immunohistochemical method. As shown in Fig. 1A, 
staining of COM1 was mainly confined in cytoplasm of bladder 
urothelial cells, with no obvious staining seen in nuclei of 
these cells or stromal tissue. Normal bladder urothelial cells 
and cancer cells of non-invasive tumours exhibited a stronger 
staining of COM1 in the cytoplasm. In contrast, the staining 
was weaker or absent from the cancer cells of invasive tumour 
tissues (Fig. 1A). Invasive tumours had significantly low levels 
of staining in comparison with non-invasive tumours (p=0.012, 
Table II). In both normal and tumour tissues, nucleic staining 
of COM1 was not demonstrated. The expression of COM1 was 
also examined in three bladder cancer cell lines using RT-PCR. 
COM1 transcript was detected in all three human bladder 
cancer cells (Fig. 1B).
Knockdown and overexpression of COM1 in bladder cancer 
cells. To investigate the impact of COM1 on functions of 
bladder cancer cells, the constructed COM1 expression vectors 
Table II. IHC staining of COM1 in bladder cancer specimens.
  Score 0 (%) Score 1 (%) Score 2 (%) Score 3 (%) Total
Normal  0 2 (40) 3 (60) 0   5
Cancer Non-invasive 0 2 (14.3) 9 (64.3) 3 (21.4) 14
 Invasive 3 (16.7) 10 (55.6) 4 (22.2) 1 (5.6) 18
Score 0, negative; score 1, faint staining; score 2, moderate staining; score 3, strong staining. COM1 staining was decreased in invasive bladder 
cancer, p=0.047 in comparison with its staining in normal bladder tissues and non-invasive bladder cancer using χ2 test. Invasive tumours had a 
significantly low level of straining compared with non-invasive tumours (p=0.012, χ2=10.9).
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and anti-COM1 ribozyme transgenes were utilised to over-
express or knockdown COM1 in bladder cancer cells, which 
were weakly positive for COM1. After the selection using blas-
ticidin, the expression of COM1 in the transfected cells was 
verified using both RT-PCR and western blot analysis (Fig. 2). 
Reduced COM1 expression of both mRNA (Fig. 2A) and 
protein (Fig. 2B) was seen in RT112 COM1rib, in comparison 
with RT112 WT and RT112 pEF, while an increased expres-
sion of COM1 was seen in RT112 COMexp compared to the 
controls. Similarly, knockdown and overexpression of COM1 
were confirmed in EJ138 COMrib and EJ138 COMexp cells 
respectively, in comparison with EJ138 WT and EJ138 pEF 
control cells.
COM1 is associated with the growth rate and invasion of 
bladder cancer cells. Following verification, influence of 
COM1 on invasiveness was examined in the genetically 
modified cells. Knockdown of COM1 in the bladder cancer 
cells rendered the cells more invasive (Fig. 3). Interestingly, 
overexpression of COM1 in these cells made the cells less 
invasive compared with the control cells. Using the same 
cells, we further tested the rate of cell growth over a 5-day 
period. RT112 COM1rib and EJ138 COM1rib both displayed 
a faster rate of growth, compared with the controls (Fig. 4). 
Furthermore, cells with forced overexpression of COM1 
displayed a slower growth rate.
Effects of COM1 on apoptosis of bladder cancer cells. In order 
to determine the mechanism by which COM1 inhibits bladder 
cancer cell growth, the proportion of apoptotic cells was 
analyzed by flow cytometry. It was demonstrated that there was 
a significantly higher proportion of apoptotic cells including 
both early apoptotic (Q4), late apoptotic and dead cells (Q2) 
in RT112 COM1exp cells (Q2 9.77% + Q4 15.64%), compared 
with the RT112 WT (Q2 7.58% + Q4 9.65%) and the RT112pEF 
(Q2 7.75% + Q4 8.36%) control (Fig. 5). There was no differ-
ence of the apoptotic population was seen in RT112COM1rib 
cells compared to both controls.
Expression of uPA, C-myc and P21 in bladder cancer cell line 
RT112. We further examined a couple of COM1 responsive 
genes which might be involved in the impact on growth and 
invasion. The mRNA expression of uPA, C-myc and P21 in 
RT112 cells were detected using RT-PCR. The expression of 
P21 was significantly higher in which bladder cancer cells that 
overexpressed COM1, and was much lower in COM1 knock-
down cells. But no significant difference was found in mRNA 
levels of uPA and C-myc (Fig. 6).
Figure 1. Expression of COM1 in bladder cancer. (A) Immunohistochemical 
staining of COM1 in human bladder tissues. Staining of COM1 was mainly 
confined in cytoplasm of bladder urothelial cells of normal bladder tissues and 
cancerous cells of non-invasive tumour specimens, little staining was seen in 
nuclei of these cells or stromal tissue. In contrast, the staining was weaker or 
absent from the cancer cells of invasive tumours. (B) The mRNA expression of 
COM1-1 in bladder cancer cell lines, RT112, EJ138 and T24. All three bladder 
cancer cell lines expressed COM1. NC, negative control.
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Figure 2. Knockdown and overexpression of COM1 in bladder cancer cells. (A) The mRNA expression of COM1 in the transfected cells by RT-PCR. mRNA 
of COM1 was knocked down in RT112 COM1rib and EJ138 COM1rib, and overexpressed in RT112 COM1exp, compared with the wild-type (RT112WT and 
EJ138WT) and empty plasmid (RT112pEF and EJ138pEF) control cells. Reduced COM1 expression of mRNA was seen in RT112 COM1rib, in comparison with 
RT112 WT and RT112 pEF, while an increased expression of COM1 was seen in RT112 COMexp compared to the controls. Similarly, knockdown and overexpres-
sion of COM1 were confirmed in EJ138 COMrib and EJ138 COMexp cells respectively, in comparison with EJ138 WT and EJ138 pEF control cells. NC, negative 
control. (B) The potein expression of COM1 (~10 kDa) in the transfected cells by western blot analysis. Protein of COM1 was knocked down in RT112 COM1rib 
and EJ138 COM1rib and overexpression in RT112 COM1exp, compared with the wild-type (RT112WT and EJ138WT) and empty plasmid (RT112pEF and 
EJ138pEF) control cells. Reduced COM1 expression of protein was seen in RT112 COM1rib, in comparison with RT112 WT and RT112 pEF, while an increased 
expression of COM1 was seen in RT112 COMexp compared to the controls. Similarly, knockdown and overexpression of COM1 were confirmed in EJ138 COMrib 
and EJ138 COMexp cells respectively, in comparison with EJ138 WT and EJ138 pEF control cells. GAPDH (38 kDa) was used as the housekeeping control.
Figure 4. Effect of COM1 expression on growth rate of bladder cancer cells. 
(A) The cell growth rate (shown are third day and fifth day) of RT112 COM1rib 
cells was significantly increased in comparison with the controls (WT and pEF, 
n=12), **p<0.01. The cell growth rate of RT112 COM1exp was significantly 
reduced compared to both controls, **p<0.01 for RT112 COM1exp versus RT112 
WT, and p<0.001 versus RT112 pEF (n=12). (B) The cell growth rate of EJ138 
COM1rib cells was significantly increased in comparison to both WT and pEF, 
**p<0.01. The experiment was repeated more than three times.
Figure 3. Effects of COM1 knockdown and overexpression on the invasion, 
in vitro. (A) RT112 cells, (B) EJ138 cells. *p<0.05 versus the respective con-
trols, **p<0.01 versus the controls. The experiment was repeated three times.
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Discussion
Bladder cancer is one of the commonly seen tumours in males 
and females and the incidence is estimated to be the 7th in the 
UK and 9th worldwide, based on the 2008 statistics (Cancer 
Research UK, 2012) Approximately 382,660 new bladder 
cancer cases occurred and 150,280 patients died of bladder 
cancer worldwide in 2008. At the same time, bladder cancer is 
the most common malignancy of the urinary tract, accounting 
for 90-95% of urothelial carcinomas (11). The feature of bladder 
cancer is apt to recurrence. At initial diagnosis, 75% patients 
present with non-muscle-invasive bladder cancer (NMIBC), the 
remaining 25% present with muscle-invasive bladder cancer 
(MIBC). The main problems of NMIBC are recurrence and 
progression, while MIBC is frequently associated with meta-
static diseases and is the major cause of mortality. In NMIBC, 
approximately 50-80% of patients will recur after managed with 
transurethral resection (TUR) and intraversical therapy (12). 
Despite the improvements in both early detection and treatment, 
there remains a significant challenge to manage this disease.
The role of COM1, in tumour progression remains unclear 
and in somewhat controversial. However, its effect on cell 
growth, i.e. whether it is stimulating or inhibiting may vary in 
different malignancies. COM1 has been found to aid the estab-
lishment of metastasis and to play a key role in the progression 
of malignancies of breast (1,5-7,13), thyroid (4,13,14), central 
nervous system (15) and pancreas (3,16,17). COM1 has been 
implicated in inducing chemoresistance in pancreatic and breast 
cancer cells, protecting them from apoptosis and making tumour 
cells genetically unstable (17). In prostate cancer, however, 
COM1 appears to have tumour suppressive activity (7). The 
current study has examined the staining pattern of COM1 in 
human bladder tissues and tested the impact on the growth, 
invasion and apoptosis of bladder cancer cells by genetically 
manipulating the expression of COM1.
Similar to human breast cancer, thyroid and prostate cancer, 
COM1 is seen at a lower level in bladder tumour cells, compared 
Figure 5. The apoptotic population in RT112 cells by flow cytometry. The apoptotic population in RT112 cells was analyzed using flow cytometry after 48 h 
of serum starvation. There was a marked increase in the population of apoptotic cells in the RT112 COM1exp cells compared to the controls. No significant 
decrease in the numbers was observed of apoptotic cells in RT112 COM1rib cells compared to the controls (WT and pEF). The experiment was repeated three 
times. Apoptotic index refers to total apoptotic population including both early apoptotic cells (Q2) and late apoptotic cells (Q4).
Figure 6. Expression of uPA, C-myc and P21 in bladder cancer cell line RT112 
in relation with COM1. The mRNA expression of uPA, C-myc and P21 in 
RT112 cells were detected using RT-PCR. The expression of P21 was signi-
ficantly higher in bladder cancer cells that overexpressed COM1 and was 
much lower in COM1 knockdown cells. No significant difference was found in 
mRNA levels of uPA and C-myc.
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with normal bladder urothelial cells and the COM1 staining 
is linked to the muscle invasion of bladder cancer. This is in 
contrast to that observed with pancreatic cancer cells, in which 
cancer cells had higher staining than normal cells. This would 
indicate that in solid human tumours, COM1 exists at lower 
levels, although the opposite may also operate. It is interesting 
to note that both normal urothelial cells and bladder cancer cells 
had little COM1 in the nucleus. The nuclear existence of COM1 
is particularly interesting as it has been suggested that the cyto-
plasmic/nuclear distribution pattern of the COM1 protein may 
be a key feature in cancer and an important reason in deciding 
the contrasting role of COM1 in different cancer types. While 
COM1 nucleic staining in breast cancer cells has been shown 
to be significantly reduced compared with normal epithelial 
cells (5), bladder cancer cells have a marked reduction in the 
cytoplasmic region while no nuclear staining was seen in normal 
and tumour cells of the bladder tissues. The current study further 
indicates the possibility of a nuclear connection in the function of 
COM1. Thus, changes in the overall level of staining of COM1 in 
bladder cancer cells and in intracellular distribution appear to be 
a feature in human bladder tumour tissues.
In the present study, we employed methods to genetically 
alter the expression of COM1 in bladder cancer cells, namely 
the ribozyme approach and overexpression approach, respec-
tively. The loss of COM1 by way of hammerhead ribozyme 
transgenes resulted in more invasiveness compared with control 
cells. In clear contrast, forced overexpression of COM1 in two 
bladder cancer cell lines, RT112 and EJ138, resulted in a reduc-
tion of invasion. This indicates that COM1 plays a key role in 
the control of the aggressiveness of bladder cancer cells. The 
current study has also demonstrated that loss of COM1 resulted 
in an accelerated cell growth in vitro. This growth regulatory 
role of COM1 has been tentatively indicated in other tumour 
cells including breast cancer cells and thyroid cancer cells, in 
which Vit D3 inhibition of cell growth was associated with a 
rise of COM1 (18,19). In pancreatic cancer cells, overexpression 
of COM1 is associated with inhibitory effects on cell growth 
and/or with accelerated apoptosis (15). This together with the 
effects observed in other solid tumours (breast, prostate and 
thyroid) (4,6,14), strongly suggest that COM1 is a potential 
tumour suppressor in these solid tumours. This suggestion is 
further supported by our in vitro results, in which COM1 exhib-
ited inhibitory effect on growth of bladder cancer cells.
In order to determine the mechanism by which COM1 
inhibits bladder cancer cell growth, the proportion of apoptotic 
cells was analyzed by flow cytometry in our study. There was 
an increased proportion of apoptotic cells (both early and late) 
in bladder cancer cells overexpressing COM1. A cyclin/cyclin 
dependent kinase (cdk) inhibitor, p21 has been shown as a target 
gene regulated by COM1 during doxobubicin induced chemo-
resistence (17). In line with this finding, an upregulation of p21 
was seen in the bladder cancer cells of COM1 overexpression. 
The role of p21 has been well studied in mediating the G1/S 
checkpoint in response to treatment with agents the induce 
genotoxic stress (20,21). It has been suggested that as a negative 
regulator of cell cycle progression, P21 has a certain role to play 
in the inhibitory effect on growth by COM1. Recently, it has been 
shown that COM1 is one of the key modulators in the antitumour 
(pro-apoptotic) effects of the cannabinoids, by mediating its 
apoptotic effect via upregulation of the endoplasmic reticulum 
stress related genes ATF-4, CHOP and TRB3 (22). COM1 may 
also exert its inhibitory effect on prostate cancer via the peroxi-
some proliferator activated receptor γ pathway (23). Together 
with the recent report that COM1 interacts with p53, a well 
established tumour suppressor in certain tumour types (15), the 
present study indicates that regulation of cell cycle and tumour 
suppressors is a key mechanism in its role in cancer progres-
sion. Further investigations would be required to elucidate the 
molecular mechanisms underlying these impacts on bladder 
cancer cells by COM1, including the candidate downstream 
responsive genes, MMP-9 and MMP-13 (24). However, one 
should bear in mind that the tumour suppressive role of COM1 
has only been confirmed in certain tumours, whereas in other 
tumour types including thyroid and pancreatic cancers, COM1 
was found to be overexpressed in tumours (3,4). In colorectal 
cancer, another intriguing example, although COM1 was found 
to be lost/reduced in tumour tissues compared with normal 
tissues (25), the molecule is anti-apoptotic and increase the 
growth of colorectal cancer cell lines in vitro (26). The tumour 
suppressive or stimulating role of COM1 appears therefore to 
be dependent upon the type of tumours, and the experimental 
conditions. It also depends on the cellular location of the protein, 
in that cytoplasmic or nuclear location of the protein may govern 
how the COM1 protein acts, clearly an interesting area to pursue 
in future studies. Finally, the link between COM1, cellular 
invasion and apoptosis as seen in the present study and recent 
studies indicates that COM1 may be a player in the regulation 
of Anoikis (27,28) and that this interesting link warrants further 
investigation.
In conclusion, the current study showed reduced expres-
sion of COM1 in invasive human bladder cancer. Together 
with our genetic manipulation study which demonstrated an 
inverse relationship between COM1 expression and the in vitro 
growth/invasion, it is concluded that COM1 is a negative regu-
lator of the growth and invasion in bladder cancer.
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